USA: A new study published in the Journal of Diabetes and Its Complications suggests that tirzepatide, a novel dual ...

Postoperative penile hypoxia is one potential contributor, Pedersen and co-authors noted. The rationale for LI-SWT to treat ...

A recent research presented at the ENDO 2025 revealed that high blood sugar levels can impact men's sexual health. The ...

Read the full paper here. The post Study finds erectile dysfunction for 1 in 5 men even years after Covid infection appeared first on Boing Boing.

A new study conducted on medical students found that those who suffer from Irritable Bowel Syndrome are 108 percent more likely to develop erectile dysfunction.

Of 609 men surveyed, 19% continued to have erectile dysfunction after being hospitalized with COVID-19. Nearly half still had ED after two years.

The health study found medications commonly prescribed for erectile dysfunction are associated with significant reductions in deaths, cardiovascular disease, and dementia ...

A new head-to-head study of tirzepatide versus semaglutide for weight loss in people living with obesity, but not diabetes, shows that over 72 weeks tirzepatide results in an average weight loss ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for weight loss in a head-to-head trial with semaglutide (Ozempic, Wegovy).

In the US alone approximately 30 million men are living with erectile dysfunction while an estimated 2 out of every 100 American males is not producing testosterone within a typical healthy range ...

New research highlights that 65.8% of diabetic men suffer from erectile dysfunction. Early detection and better diabetes control are key to reducing this common yet serious condition.

Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg or 15 mg ...